Daiichi Sankyo has something special in Enhertu. The firm is solidly profitable and has a strong balance sheet. It is trading at a premium to fair value. Daiichi Sankyo (OTCPK:DSNKY) is an ...

Daiichi Sankyo research and development global head Ken Takeshita stated: “If approved, ENHERTU could once again change the treatment paradigm for certain patients with breast cancer, pushing ...

Enhertu slashed the risk of disease progression or death by a massive 71.6% over Kadcyla in second-line HER2-positive metastatic breast cancer patients previously treated with Roche’s Herceptin ...

AstraZeneca and Daiichi Sankyo’s Enhertu is shouldering big expectations. With a new head-to-head trial win against Roche’s Kadcyla, the companies are showing their antibody-drug conjugate ...

Earnings Call Insights: Daiichi Sankyo (OTCPK:DSKYF) Q3 2024 Management ViewRevenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven ...

Daiichi Sankyo Company, Limited (hereafter, ... ENHERTU (HER2 ADC) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2 low, advanced gastric or gastroesophageal junction ...

The success of Daiichi Sankyo's Enhertu, particularly for a variety of HER2-overexpressed cancer types, was highlighted as a significant achievement.

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months ... contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).

Enhertu reduced the risk of disease progression or death by 36%, with a median PFS of 13.2 months versus 8.1 months for chemotherapy. The trial showed an ORR of 62.6% for Enhertu compared to 34.4% ...

ENHERTU is the second innovative oncology medicine to be launched in Japan from the oncology pipeline of Daiichi Sankyo in the past year Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) ...